BiotechTube

adalimumab

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ankylosing Spondylitis

Conditions

Ankylosing Spondylitis

Trial Timeline

Feb 1, 2008 → Jan 1, 2011

NCT ID
NCT00667355

About adalimumab

adalimumab is a phase 3 stage product being developed by Eisai for Ankylosing Spondylitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00667355. Target conditions include Ankylosing Spondylitis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (7)

NCT IDPhaseStatus
NCT01243671Phase 3Completed
NCT00690573Phase 3Completed
NCT00667355Phase 3Completed
NCT00445432Phase 2/3Completed
NCT00603993Phase 3Completed
NCT00235872Phase 3Completed
NCT00235833Phase 2Completed

Competing Products

20 competing products in Ankylosing Spondylitis

See all competitors
ProductCompanyStageHype Score
InfliximabCelltrionPhase 1
33
InfliximabCelltrionPhase 1
33
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
52
Ixekizumab + Placebo + AdalimumabEli LillyPhase 3
77
Tramadol /acetaminophen + DiclofenacJohnson & JohnsonApproved
85
Golimumab + PlaceboJohnson & JohnsonPhase 3
77
GolimumabJohnson & JohnsonApproved
85
SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 2/3
65
placebo for risankizumab + risankizumabAbbViePhase 2
52
AdalimumabAbbVieApproved
85
Upadacitinib + PlaceboAbbViePhase 2
52
AdalimumabAbbViePre-clinical
23
infliximab + PlaceboMerckPhase 3
77
InfliximabMerckApproved
85
Infliximab + Placebo + NaproxenMerckPhase 3
77
InfliximabMerckPre-clinical
23
GolimumabMerckApproved
85
RemicadeMerckApproved
85
RemicadeMerckApproved
85
InfliximabMerckApproved
85

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85